Brian Ohara, MD
Internal Medicine · Dickinson, NDNPI 1568459113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $531 and has fallen 75.7% since, to $129 in 2025.
Across 55 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$205
- Astellas Pharma US Inc$167
- Amgen$117
- Boehringer Ingelheim$104
- Lilly USA, LLC$88
- Novo Nordisk$86
- plus $371 from 13 others
What the payments were for
- Food & beverage$1,12799%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $205 |
| Astellas Pharma US Inc | 8 | $167 |
| Amgen | 4 | $117 |
| Boehringer Ingelheim | 4 | $104 |
| Lilly USA, LLC | 7 | $88 |
| Novo Nordisk | 6 | $86 |
| Novartis | 3 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| Exact Sciences | 2 | $33 |
| Boston Scientific | 1 | $29 |
| Johnson & Johnson | 2 | $26 |
| Pfizer | 2 | $25 |
| AbbVie | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$1,139 in reported general payments places this provider in the 85th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 99 | $98,198 |
| EliquisApixaban | 108 | $72,363 |
| Xeljanz XrTofacitinib Citrate | 12 | $70,819 |
| MounjaroTirzepatide | 56 | $57,661 |
| SynjardyEmpagliflozin/Metformin Hcl | 78 | $48,396 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 70 | $46,989 |
| JardianceEmpagliflozin | 55 | $41,205 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $33,154 |
| OzempicSemaglutide | 31 | $30,019 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $22,234 |
| XareltoRivaroxaban | 23 | $18,636 |
| EntrestoSacubitril/Valsartan | 43 | $17,558 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $16,470 |
| FarxigaDapagliflozin Propanediol | 26 | $15,829 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $12,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $88 | $155,858155 claims |
| Boehringer IngelheimSynjardy, Synjardy Xr, Jardiance | $104 | $136,590203 claims |
| PfizerEliquis | $25 | $72,363108 claims |
| Novo NordiskOzempic | $86 | $30,01931 claims |
| Johnson & JohnsonXarelto, Invokamet | $26 | $26,96436 claims |
| NovartisEntresto | $51 | $17,55843 claims |
| AstraZenecaFarxiga | $205 | $15,82926 claims |
| AbbVieCreon | $23 | $12,03518 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $39 | $5,65716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Dickinson
- Bruce OlinDickinson$8K
- Mark HinrichsDickinson$500
- Patricia AndersonDickinson$439
- Michael LillestolFargo$18K
- Khalin DendyBismarck$10K
- Gene SchwartzTrenton$6K
- Stephanie CanhamBismarck$4K
- Radu RautaBismarck$3K
- Donald GrenzBismarck$3K
- Julia SchwartzBismarck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.